CTOs on the Move


 
Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Vizgen raised $14M on 01/30/2020
Vizgen raised $85.2M on 06/03/2022

Similar Companies

Quick-Med Technologies

Quick-Med Technologies is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mountain Optical Systems Technology

Mountain Optical Systems Technology is a Boulder Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioHouston Inc

BioHouston Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.

Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.